Universal Beteiligungs und Servicegesellschaft mbH Acquires New Holdings in Twist Bioscience Corporation (NASDAQ:TWST)

Key Points

• Universal Beteiligungs und Servicegesellschaft mbH has acquired 8,297 shares of Twist Bioscience Corporation valued at approximately $326,000 in the first quarter of 2023.
• Twist Bioscience reported a quarterly loss of ($0.66) earnings per share, missing analysts' estimates, while revenue for the quarter was $92.79 million, exceeding expectations.
• The stock has a market capitalization of $2.02 billion and recent analyst ratings indicate a consensus of "Moderate Buy" with an average price target of $50.40.

Universal Beteiligungs und Servicegesellschaft mbH bought a new position in Twist Bioscience Corporation (NASDAQ:TWST - Free Report) in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund bought 8,297 shares of the company's stock, valued at approximately $326,000.

Other institutional investors have also modified their holdings of the company. First Light Asset Management LLC acquired a new stake in shares of Twist Bioscience during the 4th quarter worth about $56,984,000. Marshall Wace LLP boosted its position in Twist Bioscience by 15,927.8% during the fourth quarter. Marshall Wace LLP now owns 846,107 shares of the company's stock worth $39,319,000 after purchasing an additional 840,828 shares during the period. Renaissance Technologies LLC raised its stake in Twist Bioscience by 86.0% in the fourth quarter. Renaissance Technologies LLC now owns 398,708 shares of the company's stock valued at $18,528,000 after purchasing an additional 184,398 shares in the last quarter. Norges Bank purchased a new position in shares of Twist Bioscience in the fourth quarter worth $7,584,000. Finally, D. E. Shaw & Co. Inc. lifted its stake in Twist Bioscience by 1,085.9% during the 4th quarter. D. E. Shaw & Co. Inc. now owns 107,268 shares of the company's stock valued at $4,985,000 after acquiring an additional 98,223 shares during the period.

Twist Bioscience Trading Down 5.6%

NASDAQ:TWST traded down $1.45 on Thursday, reaching $24.45. The company's stock had a trading volume of 1,381,401 shares, compared to its average volume of 1,135,391. The business's 50-day moving average price is $34.63 and its two-hundred day moving average price is $38.42. Twist Bioscience Corporation has a 1-year low of $24.37 and a 1-year high of $55.33. The company has a debt-to-equity ratio of 0.03, a quick ratio of 4.24 and a current ratio of 3.90. The firm has a market cap of $1.47 billion, a PE ratio of -16.86 and a beta of 2.36.

Twist Bioscience (NASDAQ:TWST - Get Free Report) last posted its quarterly earnings data on Monday, August 4th. The company reported ($0.47) earnings per share for the quarter, topping the consensus estimate of ($0.54) by $0.07. The firm had revenue of $96.06 million during the quarter, compared to analyst estimates of $95.52 million. Twist Bioscience had a negative return on equity of 29.03% and a negative net margin of 23.51%. Equities research analysts anticipate that Twist Bioscience Corporation will post -2.12 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

TWST has been the topic of a number of research reports. Evercore ISI set a $46.00 price target on Twist Bioscience in a research note on Monday. Guggenheim reiterated a "buy" rating and set a $50.00 price objective on shares of Twist Bioscience in a research report on Tuesday, May 6th. Barclays lowered their price target on shares of Twist Bioscience from $58.00 to $45.00 and set an "overweight" rating on the stock in a report on Thursday, April 10th. Robert W. Baird dropped their price target on shares of Twist Bioscience from $54.00 to $44.00 and set an "outperform" rating for the company in a research report on Tuesday, May 6th. Finally, Cowen reissued a "buy" rating on shares of Twist Bioscience in a research report on Monday. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and nine have issued a buy rating to the company's stock. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average target price of $49.40.

Insider Activity

In related news, COO Patrick John Finn sold 1,877 shares of Twist Bioscience stock in a transaction dated Wednesday, May 21st. The stock was sold at an average price of $29.75, for a total value of $55,840.75. Following the completion of the transaction, the chief operating officer owned 240,783 shares in the company, valued at approximately $7,163,294.25. This trade represents a 0.77% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CEO Emily M. Leproust sold 2,802 shares of the company's stock in a transaction on Wednesday, May 21st. The stock was sold at an average price of $29.75, for a total value of $83,359.50. Following the transaction, the chief executive officer directly owned 649,630 shares in the company, valued at approximately $19,326,492.50. The trade was a 0.43% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 13,109 shares of company stock worth $425,962. Insiders own 3.01% of the company's stock.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.